Aether Industries Q1 Results: Net profit rises 33% YoY to ₹627 crore
Aether Industries reported a 27% rise in Q1FY27 revenue to ₹3,266 million and a 33% jump in net profit to ₹627 million. EBITDA margins expanded to 31%. The company launched an exclusive R&D partnership with Dow Chemical for silicones and began commercializing new LSM products from its Panoli facility.
*this image is generated using AI for illustrative purposes only.
Aether Industries Limited delivered robust financial performance in the first quarter of fiscal year 2027, driven by strong demand in its contract manufacturing segments and successful capacity utilization at new sites. Consolidated revenue from operations rose by 27% year-on-year to ₹3,266 million, up from ₹2,566 million in the corresponding quarter of the previous fiscal year. Net profit after tax (PAT) increased by 33% to ₹627 million, compared to ₹470 million in Q1 FY26. EBITDA grew by 31% to ₹1,028 million, expanding margins from 30% to 31%. This growth underscores the company’s strategic shift towards higher-margin contract models and its ability to scale complex chemistries.
The financial filing was submitted to BSE Limited and National Stock Exchange of India Limited in accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The earnings conference call was held on July 31, 2026, with participation from Dr. Aman Desai, Promoter and Whole Time Director; Mr. Rohan Desai, Promoter and Whole Time Director; and Mr. Faiz Nagariya, Chief Financial Officer. Management highlighted that the final insurance claim for fixed assets lost in the November 29, 2023 fire accident was received during the quarter, completing the recovery process.
Financial Performance Highlights
The company’s profitability metrics improved across the board, reflecting operational efficiency and favorable product mix shifts. The PAT margin widened to 19% from 18% in the prior year period. Capital expenditure for the quarter stood at ₹943 million, with full-year guidance for FY27 set between ₹3,000 million and ₹3,500 million. These investments are primarily directed towards Site 5 (Magnum) and the new R&D facility.
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue from Operations | ₹3,266 million | ₹2,566 million | 27% |
| EBITDA | ₹1,028 million | ₹785 million | 31% |
| EBITDA Margin | 31% | 30% | +100 bps |
| Net Profit After Tax | ₹627 million | ₹470 million | 33% |
| PAT Margin | 19% | 18% | +100 bps |
| Capital Expenditure | ₹943 million | — | — |
Strategic Expansion and New Partnerships
Aether Industries announced a landmark exclusive multi-year research collaboration with Dow Chemical to develop new manufacturing technologies for silicones. The program will be conducted at Aether’s R&D and pilot plant facilities in Surat, Gujarat. Dr. Aman Desai noted that silicones are a strategically important class of high-performance materials, with India currently importing the bulk of its foundational molecules. This partnership aims to address India’s multi-billion-dollar silicones market through indigenous technology development, leveraging Aether’s core competencies in process chemistry and scale-up capabilities.
Additionally, the company began commercial sales of new Large Scale Manufacturing (LSM) products from its Magnum site (Site 5) in Panoli during the quarter. These products, priced in the $30 to $40 per kilo range, are designed for pharmaceutical, agrochemical, and material science applications. Rohan Desai stated that these molecules are being manufactured in India for the first time, representing a clear import substitution opportunity. The company expects these products to contribute to revenue starting in Q2 FY27.
Operational Updates and Capacity Utilization
Site 3++, commissioned in February 2026, is ramping up as expected and contributing meaningfully to commercial output. Site 5, dedicated to Baker Hughes and oil and gas sector requirements, continues to scale on the back of long-term strategy contracts. Capacity utilization across existing plants was reported as follows: Site 2 at 74%, Site 3 at 69%, and Site 4 at 59%.
Management emphasized that the Contract Exclusive Manufacturing (CEM) and Contract Research and Manufacturing Services (CRAMS) models are becoming the backbone of the business, with CEM running at EBITDA margins north of 28% to 30%. In Q1 FY27, the company onboarded 10 new marquee clients and cleared more than nine customer certification audits. Working capital intensity remains a focus area, with inventory levels elevated due to strategic raw material positioning for Site 3++ and Site 5. However, management anticipates a progressive decline in working capital days as revenues from these new sites materialize.
Historical Stock Returns for Aether Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.85% | +2.57% | +11.86% | +68.07% | +116.10% | +109.85% |
How might the exclusive collaboration with Dow Chemical impact Aether Industries' long-term revenue mix and technological moat in the silicones sector?
What are the specific regulatory or operational hurdles Aether faces in scaling the new Large Scale Manufacturing (LSM) products from Site 5 to meet full-year guidance?
Given the elevated working capital intensity due to strategic inventory positioning, when does management expect cash conversion cycles to normalize as Site 3++ and Site 5 ramp up?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
